<DOC>
	<DOCNO>NCT02311413</DOCNO>
	<brief_summary>The goal study identify change cell related treatment Cat-PAD ( ToleroMune Cat ) .</brief_summary>
	<brief_title>Fel 1 Peptide Immunotherapy Clinical Trial</brief_title>
	<detailed_description>Cat-PAD experimental cat allergy vaccine study determine reduce symptom score participant expose cat allergen . To study vaccine cause change immune system , researcher plan evaluate change blood ( gene protein ) urine response Cat-PAD vaccine .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Individuals meet follow criterion eligible enrollment study participant : Subject must able understand provide informed consent ; Subjects without asthma asthma Global Initiative Asthma ( GINA ) Step 1 treatment inhale shortacting beta2agonist GINA Step 2 3 treatment inhale corticosteroid . Treatment asthma must stable ( drug ( ) , dose , frequency ) least 4 week prior randomization . The dose inhaled corticosteroid must great 500 microg fluticasone equivalent ( e.g. &gt; 00 microg budesonide ; &gt; 400 microg mometasone ) per day treatment asthma ; A minimum 1year documented history allergic rhinoconjunctivitis exposure cat ; Positive skin prick test cat hair ( wheal diameter 3mm large negative control . Cat specific IgE great equal 0.35IU/ml ; Subjects must express one ( ) follow Human Leukocyte Antigens ( HLA ) : HLADRB1*0101 , HLADRB1*0301 , HLADRB1*0401 , HLADRB1*0405 , HLA DRB1*0701 , HLADRB1*0901 , HLADRB1*1001 , HLADRB1*1101 , HLADRB1*1301 , HLADRB1*1401 , HLADRB5*0101 . Not limited list HLA may become available future ; FEV1 must decrease &gt; 20 % baseline prior nasal allergen challenge , return baseline inhalation 200Âµg Salbutamol . Baseline define FEV1 value Visit PreScreening ; Screening nasal allergen challenge TNSS le equal 4 baseline great equal high dose , Between first nonzero dose 10 minute high dose , either ; 3 sneeze count , great 20 % drop PNIF record , discretion Physician ; Subjects must regular exposure ( minimum 1 hour exposure twice per week ) cat normal living work circumstance ; Willing able comply study requirement ; If subject female childbearing potential must stable highly effective contraceptive method least 3 month prior screen continue study , produce negative urine pregnancy test visit . Subject may include without negative urine pregnancy test document surgically sterile least 2 year postmenopausal . Highly effective contraceptive method may include : Total sexual abstinence total duration study include washout period ; Vasectomised sexual partner ( appropriate postvasectomy documentation absence sperm ejaculate ) + male condom ; Tubal occlusion + male condom ; Intrauterine device ( IUD ) , provide coil copper band + male condom ; Intrauterine system ( IUS ) Levonorgestrel , e.g . Mirena + male condom ; Medroxyprogesterone injection ( DepoProvera ) + male condom ; Etonogestrel implant ( e.g . Implanon , Norplant ) + male condom ; Normal low dose combine oral pill + male condom ; Norelgestromin /EE transdermal system + male condom ; Intravaginal device , e.g . EE etonogestrel + male condom ; Cerazette ( TM ) ( desogestrel ) + male condom . Individuals meet criterion eligible enrollment study participant : Inability unwillingness participant give write informed consent comply study protocol ; Asthma symptom unstable 12 week prior study entry requirement oral corticosteroid treat asthma 6 month prior study entry 12 week prior randomization ; Any history intubation/lifethreatening episode asthma exacerbation ; Hospitalization asthma year prior screening . ; A history anaphylaxis cat allergen . As define ; ( 1 ) one organ system involvement symptom urticaria , wheeze , shortness breath , abdominal pain , vomiting , ( 2 ) presence hypotension cyanosis , loss consciousness ; Subjects FEV1 &lt; 0 % predict ; Subjects FEV1/FVC ratio &lt; 70 ; History significant recurrent acute sinusitis , define 2 episode per year last 2 year , require antibiotic treatment ; At time screening , current symptom , treatment , upper respiratory tract infection , acute sinusitis , acute otitis medium , relevant infectious process ; serous otitis medium exclusion criterion . Subjects may evaluate eligibility symptom resolve maintain Subject Screening number ; The subject unacceptable symptom 5 day without oral antihistamine prior screen visit ; Treatment omalizumab within 6 month screen ; Previous allergen immunotherapy cat allergy ; Subjects administration epinephrine contraindicate ; Subjects treat betablockers ; Symptoms clinically relevant illness , Investigator 's opinion , within 6 week prior Screening Visit ; Female subject pregnant , lactate planning pregnancy ; Any clinically relevant abnormality physical examination ; Vital sign ( blood pressure , pulse , respiratory rate , body temperature ) outside normal limit unless consider clinically relevant Investigator ; Laboratory value ( haematology , biochemistry , urine test ) outside normal range , unless consider clinically relevance Investigator . Hemoglobin must great 12g/dl visit 1 , 3 4 . If hemoglobin &lt; 12g/dl visit reschedule within 2 week discretion investigator/physician hemoglobin measurement repeat subsequent visit ; History alcohol drug abuse ; History immunopathological disease may confound study outcome ; Previous participation CatPAD study ; A history severe drug allergy , severe angioedema anaphylactic reaction food ; Received treatment investigational drug within 3 month prior study ; Unable communicate understand requirement study , would impair communication subject Investigator thereby interfere informed consent procedure gathering study data ; A history significant disease disorder ( e.g . autoimmune , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment , severe atopic dermatitis ) , opinion Investigator , may either put subject risk participation study , influence result study , subject 's ability participate study ; Past current medical problem finding physical examination laboratory test list , , opinion investigator , may pose additional risk participation study , may interfere participant 's ability comply study requirement may impact quality interpretation data obtain study ; A know allergy thioglycerol ; Known history positive test result Hepatitis B , Hepatitis C , HIV tuberculosis would anticipate follow vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>